Document Detail

Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
MedLine Citation:
PMID:  23377751     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the effects of subconjunctival injection and topical application of bevacizumab and sunitinib on experimentally induced corneal neovascularization (CNV).
METHODS: CNV was induced by sutures in the right eyes of 36 rabbits. After suture removal, the rabbits were divided into 6 groups with 6 rabbits in each group. In groups 1, 2, and 3, the eyes received a subconjunctival injection of 0.1 mL of normal saline, 2.5 mg/0.1 mL of bevacizumab, and 0.25 mg/0.1 mL of sunitinib, respectively, immediately after suture removal. A booster injection of the same agent was repeated 1 week later in each group. In groups 4, 5, and 6, the eyes received topical applications of saline, bevacizumab (5 mg/mL), and sunitinib (0.5 mg/mL), respectively. These solutions were applied twice a day for 2 weeks, starting immediately after suture removal. CNV was analyzed through biomicroscopy and through histological examination using hematoxylin and eosin and CD31 immunohistochemical staining.
RESULTS: On day 14, the mean percentages of areas of CNV in sunitinib-treated eyes were smaller compared with saline-treated or bevacizumab-treated eyes in both the subconjunctival (P = 0.003 and 0.032, respectively) and topical groups (P < 0.001 in both). The topical administration of sunitinib was significantly more effective than the subconjunctival injection of the same drug at 1 week (P = 0.011). Upon histological examination of samples from the topical group, sunitinib-treated eyes showed lower vascularity than saline-treated and bevacizumab-treated eyes (P = 0.036 and 0.046, respectively).
CONCLUSIONS: These results suggest that sunitinib is more effective than bevacizumab for the inhibition of CNV. Furthermore, topical administration of sunitinib yields better results than a subconjunctival injection of the same medication.
Byung-Yi Ko; Young-Sung Kim; Sung-Gook Baek; Gun-woong Lee; Jae-Min Kim; Woo-Sean Jean; Nam-Seob Lee; Jaeku Kang
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cornea     Volume:  32     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-09     Completed Date:  2013-08-07     Revised Date:  2013-12-17    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  689-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, CD31 / metabolism
Conjunctiva / drug effects
Corneal Neovascularization / drug therapy*,  metabolism,  pathology
Disease Models, Animal*
Immunoenzyme Techniques
Indoles / therapeutic use*
Pyrroles / therapeutic use*
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Antigens, CD31; 0/Indoles; 0/Pyrroles; 0/Vascular Endothelial Growth Factor A; 0/sunitinib; 2S9ZZM9Q9V/bevacizumab
Comment In:
Cornea. 2013 Dec;32(12):e193   [PMID:  24145627 ]
Cornea. 2013 Dec;32(12):e193-4   [PMID:  24162752 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Refractory Major Depression Successfully Treated With Electroconvulsive Therapy in a Patient With Ad...
Next Document:  Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates...